MLchartDataset catalogue

Padcev

Term · Oncology and biomedicine · MLC-T-ONC-006251

A drug used alone or with pembrolizumab to treat adults with certain types of urothelial cancer (a type of cancer in the bladder or urinary tract) that have spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Padcev contains a monoclonal antibody that binds to a protein called nectin-4, which is found on some cancer cells. It also contains an anticancer drug, which may help kill cancer cells. Padcev may also help the immune system kill cancer cells. It is a type of antibody-drug conjugate. Also called enfortumab vedotin.

Table 1. Record
IdentifierMLC-T-ONC-006251
FieldOncology and biomedicine
Synonymsenfortumab vedotin
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-006251",
  "term": "Padcev",
  "field": "Oncology and biomedicine",
  "definition": "A drug used alone or with pembrolizumab to treat adults with certain types of urothelial cancer (a type of cancer in the bladder or urinary tract) that have spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Padcev contains a monoclonal antibody that binds to a protein called nectin-4, which is found on some cancer cells. It also contains an anticancer drug, which may help kill cancer cells. Padcev may also help the immune system kill cancer cells. It is a type of antibody-drug conjugate. Also called enfortumab vedotin.",
  "synonyms": [
    "enfortumab vedotin"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/padcev/"
}

Record 12,504 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.